UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 275

Sortiert nach

Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma

Clinical and experimental immunology, 2019-07, Vol.197 (1), p.74-82

2019

Link zum Volltext

Verfügbarkeit prüfen

Acute liver graft rejection after ipilimumab therapy

Annals of oncology, 2017-10, Vol.28 (10), p.2619-2620

2017

Link zum Volltext

Verfügbarkeit prüfen

Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin

British journal of cancer, 2015-12, Vol.113 (11), p.1548-1555

2015

Link zum Volltext

Verfügbarkeit prüfen

Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study

Journal of clinical oncology, 2004-03, Vol.22 (6), p.1118-1125

2004

Link zum Volltext

Verfügbarkeit prüfen

Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma

Journal of clinical oncology, 2000-01, Vol.18 (1), p.158-166

2000

Link zum Volltext

Verfügbarkeit prüfen

Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment

ESMO open, 2022-10, Vol.7 (5), p.100588-100588, Article 100588

2022

Link zum Volltext

Verfügbarkeit prüfen

Phase I II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA

Cancer gene therapy, 2006-10, Vol.13 (10), p.905-918

2006

Link zum Volltext

Verfügbarkeit prüfen

Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b

European journal of cancer (1990), 2012-09, Vol.48 (13), p.2012-2019

2012

Link zum Volltext

Verfügbarkeit prüfen

A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours

Cancer chemotherapy and pharmacology, 2015-10, Vol.76 (4), p.785-792

2015

Link zum Volltext

Verfügbarkeit prüfen

Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours

British journal of cancer, 2012-05, Vol.106 (11), p.1728-1734

2012

Link zum Volltext

Verfügbarkeit prüfen

Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients

British journal of cancer, 2005-10, Vol.93 (7), p.749-756

2005

Link zum Volltext

Verfügbarkeit prüfen

Results from a first in man Phase I/II adjuvant Dendritic Cell Vaccine study in high risk prostate cancer patients following radical surgery

Cytotherapy (Oxford, England), 2017-05, Vol.19 (5), p.S15-S15

2017

Link zum Volltext

Verfügbarkeit prüfen

Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report

European journal of cancer (1990), 2003, Vol.39 (1), p.70-77

2003

Link zum Volltext

Verfügbarkeit prüfen

27IN - The Importance of Patient Selection in Treatment Efficacy

Annals of oncology, 2012-09, Vol.23, p.ix32-ix32

Aamdal, S.

2012

Link zum Volltext

Verfügbarkeit prüfen

The Importance of Patient Selection in Treatment Efficacy

Annals of oncology, 2012-09, Vol.23, p.ix32

Aamdal, S.

2012

Link zum Volltext

Verfügbarkeit prüfen

104 INVITED Vaccine approaches to kidney cancer in the era of tyrosine kinase inhibitors

European journal of cancer supplements, 2007, Vol.5 (4), p.29-29

Aamdal, S

2007

Link zum Volltext

Verfügbarkeit prüfen

Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment

Journal of clinical oncology, 1998-10, Vol.16 (10), p.3426-3432

1998

Link zum Volltext

Verfügbarkeit prüfen

Health-related quality of life (HRQOL) in the Nordic randomized trial of adjuvant intermediate-dose interferon alfa-2b in high-risk melanoma

JOURNAL OF CLINICAL ONCOLOGY, 2011, Vol.29 (15_suppl), p.8547-8547

2011

Link zum Volltext

Verfügbarkeit prüfen

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

Journal of translational medicine, 2011-11, Vol.9 (1), p.204-204, Article 204

2011

Link zum Volltext

Verfügbarkeit prüfen

Clinical experiences with therapeutic DC vaccines targeting autologous cancer stem cells in glioblastoma

Cytotherapy (Oxford, England), 2013-04, Vol.15 (4), p.S14-S14

2013

Link zum Volltext

Verfügbarkeit prüfen

hTERT/survivin mRNA-loaded dendritic cell vaccination combined with ex-vivo expanded T cell transfer in stage IV melanoma patients show a longer overall survival in patients with sustained immune responses against hTERT

Cytotherapy (Oxford, England), 2014-04, Vol.16 (4), p.S22-S22

2014

Link zum Volltext

Verfügbarkeit prüfen

SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance

The pharmacogenomics journal, 2010-12, Vol.10 (6), p.513-523

2010

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of E7070 in patients with metastatic melanoma

Annals of oncology, 2005-01, Vol.16 (1), p.158-161

2005

Link zum Volltext

Verfügbarkeit prüfen

Telomerase peptide vaccine combined with ipilimumab in metastatic melanoma: Reports from a phase I trial

Annals of oncology, 2017-09, Vol.28, p.v410-v410

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 275

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(259)
Mit Volltextzugriff
(243)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(138)
Life Sciences & Biomedicine
(131)
Humans
(127)
Oncology
(89)
Male
(83)
Female
(81)
Middle Aged
(74)
Biological And Medical Sciences
(70)
Adult
(68)
Medical Sciences
(64)
Aged
(63)
Pharmacology. Drug Treatments
(41)
Melanoma - Drug Therapy
(37)
Antineoplastic Agents
(33)
Animals
(27)
Melanoma
(25)
Tumors
(24)
Chemotherapy
(22)
Adolescent
(19)
Antineoplastic Agents - Therapeutic Use
(19)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma

Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 ‘CREATE’

Acute liver graft rejection after ipilimumab therapy

Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin

Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study

Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma

Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment

Phase I II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA

Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b

A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours

Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours

Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients

Results from a first in man Phase I/II adjuvant Dendritic Cell Vaccine study in high risk prostate cancer patients following radical surgery

Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report

27IN - The Importance of Patient Selection in Treatment Efficacy

The Importance of Patient Selection in Treatment Efficacy

104 INVITED Vaccine approaches to kidney cancer in the era of tyrosine kinase inhibitors

Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment

Health-related quality of life (HRQOL) in the Nordic randomized trial of adjuvant intermediate-dose interferon alfa-2b in high-risk melanoma

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma

Clinical experiences with therapeutic DC vaccines targeting autologous cancer stem cells in glioblastoma

hTERT/survivin mRNA-loaded dendritic cell vaccination combined with ex-vivo expanded T cell transfer in stage IV melanoma patients show a longer overall survival in patients with sustained immune responses against hTERT

SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance

Phase II study of E7070 in patients with metastatic melanoma

Telomerase peptide vaccine combined with ipilimumab in metastatic melanoma: Reports from a phase I trial

Suchergebnisse filtern